Top

Published in:

01-05-2011 | Original Article

Dialysate CA125 levels after 5 years on continuous peritoneal dialysis

Authors: Cengiz Candan, Pınar Turhan, Lale Sever, Mahmut Civilibal, Nur Canpolat, Salim Caliskan, Ozgur Kasapcopur, Nil Arisoy

Published in: Pediatric Nephrology | Issue 5/2011

Abstract

The aim of this study was to evaluate longitudinal changes in dialysate cancer antigen 125 (dCA125) levels over time and to analyze relationships between dCA125 and peritoneal glucose exposure (PGE) in children undergoing long-term peritoneal dialysis (PD). The study group included seven boys and four girls (mean age 13 ± 5.1 years) with a mean PD duration of 84.0 ± 1.1 months. A peritoneal equilibration test (PET) was performed, and dCA125 levels were measured in all patients. Peritoneal appearance rates (AR) of dCA125, the velocity of the decrease in dCA125AR values, and annual PGE levels were also calculated. The final tests were performed at a mean of 63.3 ± 3.5 months after the initial ones. Both dCA125 and dCA125AR levels showed statistically significant decrements during the follow-up period (p = 0.003), with the velocity of decrease in dCA125AR found to be 52.6 ± 19.4%. There were no significant differences in peritoneal transport parameters between the beginning and end of the study period. PGE values were significantly higher in the last year of the study than in the first year (p = 0.014), but the velocity of the decrease in dCA125AR levels was not related to total PGE. In conclusion, a significant decline was found in dCA125 and CA125 AR levels, reflecting mesothelial cell mass, in children undergoing long-term PD (>5 years), but these were not related to PGE.

Williams JD, Kathrine JC, Topley N, von Ruhland C, Fallon M, Newman GR, Mackenzie RK, Williams GT (2002) Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 13:470–479PubMed

Saxena R (2008) Pathogenesis and treatment of peritoneal membrane failure. Pediatr Nephrol 23:695–703PubMedCrossRef

Davies S, Phillips L, Griffiths AM, Russell LH, Naish PF, Russell GI (1998) What really happens to people on long-term peritoneal dialysis? Kidney Int 54:2207–2217PubMedCrossRef

Fusshoeller A (2008) Histomorphological and functional changes of the peritoneal membrane during long-term peritoneal dialysis. Pediatr Nephrol 23:19–255PubMedCrossRef

Schaefer F, Klaus G, Muller-Wiefel DE, Mehls O, Mid European Pediatric Peritoneal Dialysis Study Group (MEPPS) (1999) Current practice of peritoneal dialysis in children: results of a longitudinal survey. Perit Dial Int 19:S445–S449PubMed

Davies SJ, Phillips L, Naish PF, Russell GI (2001) Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 12:1046–1051PubMed

Witowski J, Wisniewska J, Korybalska K, Bender TO, Breborowicz A, Gahl GM, Frei U, Passlick-Deetjen J, Jörres A (2001) Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 12:2434–2441PubMed

Witowski J, Jörres A (2005) Effects of peritoneal dialysis solutions on the peritoneal membrane: clinical consequences. Perit Dial Int 25(S3):S31–S34PubMed

Yanez-Mo M, Lara-Pezzi E, Selgas R, Ramírez-Huesca M, Domínguez-Jiménez C, Jiménez-Heffernan JA, Aguilera A, Sánchez-Tomero JA, Bajo MA, Álvarez V, Castro A, del Peso G, Cirujeda A, Gamallo C, Sánchez-Madrid F, López-Cabrera M (2003) Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 348:403–413PubMedCrossRef

10.

Krediet RT, Sampimon DE, Vlijm A, Coester AM, Struijk DG, Smit W (2009) Biological markers in the peritoneal dialysate effluent: are they useful. Contrib Nephrol 163:90–95PubMedCrossRef

11.

Visser CE, Brouwer-Steenbergen JJE, Betjes MGH, Koomen GCM, Belen RHJ, Krediet RT (1995) Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients. Nephrol Dial Transplant 10:64–69PubMed

12.

Krediet RT (2001) Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis. Perit Dial Int 21:560–567PubMed

13.

Pannekeet MM, Koomen GCM, Struijk DG, Krediet RT (1995) Dialysate CA125 in stable CAPD patients: no relation with transport parameters. Clin Nephrol 44:248–254PubMed

14.

Ho-dac-Pannekeet MM, Hiralall JK, Struijk DG, Krediet RT (1997) Markers of peritoneal mesothelial cells during treatment with peritoneal dialysis. Adv Perit Dial 13:17–22PubMed

15.

Ho-dac-Pannekeet MM, Hiralall JK, Struijk DG, Krediet RT (1997) Longitudinal follow-up of CA125 in peritoneal effluent. Kidney Int 51:888–893PubMedCrossRef

16.

Rodrigues AS, Martins M, Korevaar JC, Silva S, Oliveira JC, Cabrita A, Castro e Melo J, Krediet RT (2007) Evaluation of peritoneal transport and membrane status in peritoneal dialysis: focus on incident fast transporters. Am J Nephrol 27:84–91PubMedCrossRef

17.

Bouts AHM, Groothoff JW, van Amstel SP, Zweers MM, Davin JC, Krediet RT (2000) Dialysate CA125 levels in children treated with peritoneal dialysis. Adv Perit Dial 16:328–331PubMed

18.

Turhan P, Sever L, Caliskan S, Kasapcopur Ö, Sever A, Hacibekiroglu M, Arisoy N (2005) Dialysate CA125 levels in children on continuous peritoneal dialysis. Pediatr Nephrol 20:1615–1621PubMedCrossRef

19.

Warady BA, Alexander SR, Hossli S, Vonesh E, Geary D, Watkins S, Salusky IB, Kohaut EC (1996) Peritoneal membrane transport function in children receiving long-term dialysis. J Am Soc Nephrol 7:2385–2891PubMed

20.

Vonesh EF, Burkart J, McMurray SD, Williams PF (1996) Peritoneal dialysis kinetic modelling: validation in a multicenter clinical study. Perit Dial Int 16:471–481PubMed

21.

Pannekeet MM, Zemel D, Koomen GCM, Struijk DG, Krediet RT (1995) Dialysate markers of peritoneal tissue during peritonitis and in stable CAPD. Perit Dial Int 15:217–225PubMed

22.

Kawanishi H, Moriishi M, Harada Y, Sakikubo NT, Tsuchiya S (2000) Necessity of correcting cancer antigen 125 appearance rates by body surface area. Adv Perit Dial 16:22–25PubMed

23.

Jimenez C, Diaz C, Selgas R, Bajo MA, del Paso G, Sanchez-Tomero JA, Gonzalez-Gancedo P (1999) Peritoneal kinetics of cancer antigen 125 in peritoneal dialysis patients: the relationship with peritoneal outcome. Adv Perit Dial 15:36–39PubMed

24.

Koomen GC, Betjes MG, Zemel D, Krediet RT, Hoek FJ (1994) Cancer antigen 125 is locally produced in the peritoneal cavity during continuous ambulatory peritoneal dialysis. Perit Dial Int 14:132–136PubMed

25.

Sanusi AA, Zweers MM, Weening JJ, de Waart DR, Struijk DG, Krediet RT (2001) Expression of cancer antigen 125 by peritoneal mesothelial cells is not influenced by duration of peritoneal dialysis. Perit Dial Int 21:495–500PubMed

26.

Topley N, Michael D, Bowen T (2005) CA125: Holy grail or a poisoned chalice. Nephron Clin Pract 100:c52–c54PubMedCrossRef

27.

Jones S, Holmes CJ, Krediet RT, Mackenzie R, Faict D, Tranaeus A, Williams JD, Coles GA, Topley N (2001) Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 59:1529–1538PubMedCrossRef

28.

Fusshoeller A, Plail M, Grabensee B, Plum J (2004) Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study. Nephrol Dial Transplant 19:2101–2106PubMedCrossRef

29.

Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, Wanner C, Schneider H, Henle T, Ritz E (2003) Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 63:298–305PubMedCrossRef

30.

Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, Passlick-Deetjen J, Euro Balance Trial Group (2004) The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 66:408–418PubMedCrossRef

31.

Haas S, Schmitt CP, Arbeiter K, Bonzel KE, Fischbach M, John U, Pieper AK, Schaub TP, Passlick-Deetjen J, Mehls O, Schaefer F (2003) Improved acidosis correction and recovery of mesothelial cell mass with neutral-pH bicarbonate dialysis solution among children undergoing automated peritoneal dialysis. J Am Soc Nephrol 14:2632–2638PubMedCrossRef

32.

Witowski J, Topley N, Jörres A, Liberek T, Coles GA, Williams JD (1995) Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis. Kidney Int 47:282–293PubMedCrossRef

33.

Schmitt CP, Haraldsson B, Doetschmann R, Zimmering M, Greiner C, Böswald M, Klaus G, Passlick-Deetjen J, Schaefer F (2002) Effects of pH-neutral, bicarbonate-buffered dialysis fluid on peritoneal transport kinetics in children. Kidney Int 61:1527–1536PubMedCrossRef

34.

Breborowicz A, Breborowicz M, Pyda M, Polubinska A, Oreopoulos D (2005) Limitations of CA125 as an index of peritoneal mesothelial cell mass. Nephron Clin Pract 100:c46–c51PubMedCrossRef

35.

Davies SJ, Bryan J, Phillips L, Russell GI (1996) Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 11:498–506PubMed

36.

del Peso G, Fernández-Reyes MJ, Hevia C, Bajo MA, Castro MJ, Cirugeda A, Sánchez-Tomero JA, Selgas R (2005) Factors influencing peritoneal transport parameters during the first year on peritoneal dialysis: peritonitis is the main factor. Nephrol Dial Transplant 20:1201–1206PubMedCrossRef

Title: Dialysate CA125 levels after 5 years on continuous peritoneal dialysis
Authors: Cengiz Candan
Pınar Turhan
Lale Sever
Mahmut Civilibal
Nur Canpolat
Salim Caliskan
Ozgur Kasapcopur
Nil Arisoy
Publication date: 01-05-2011
Publisher: Springer-Verlag
Published in: Pediatric Nephrology / Issue 5/2011
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-011-1764-6

At a glance: The STEP trials

Springer Medicine

Dialysate CA125 levels after 5 years on continuous peritoneal dialysis

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2011

Alport syndrome and leiomyomatosis: the first deletion extending beyond COL4A6 intron 2

Rituximab for refractory cases of childhood nephrotic syndrome

Exchange transfusion as rescue therapy in a severely ill premature child with acute renal failure

Unilateral localized cystic kidney: Question

In memoriam: Professor Juan Rodríguez Soriano (1933–2010)

Liver fibrosis in recessive multicystic kidney diseases: transient elastography for early detection